+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Systemic Amyloidosis Market: By Type, Amyloidosis Associated with Multiple Myeloma, Secondary Systemic Amyloidosis and Others & By Region - Forecast 2016-2021

  • ID: 3974169
  • Report
  • 165 pages
  • IndustryARC
1 of 2
Amyloids are the substance made up of abnormally formed protein in the bone marrow that gets saturated in different tissues or organs of the body. The condition is termed as amyloidosis. Amyloidosis is a clinical disorder caused by extracellular and/or intracellular deposition of insoluble abnormal amyloid fibrils that alter the normal function of tissues. Systemic amyloidosis (AL amyloidosis or just primary amyloidosis) is a medical condition which involves the mesenchymal tissue, the tongue, heart, gastrointestinal tract, and skin. Globally increasing awareness about systemic amyloidosis amongst people and increasing investment by companies to develop effective and new treatments is expected to drive the global demand for systematic amyloidosis market during the period of study.

This report identifies the global systemic amyloidosis market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global systemic amyloidosis market.

Geographically North America dominated global systemic amyloidosis market due to because of high awareness, higher percentage of total income spent on healthcare compared to other economies and appropriate reimbursement circumstances and well developed healthcare infrastructure. North America was followed by Europe and Asia-Pacific as second and third largest consumer of systemic amyloidosis. Asia Pacific is projected to have fastest growth, owing to rapidly expanding healthcare infrastructure, increasing awareness especially in the major regional economies such as India and China in the region.
This report segments global systemic amyloidosis market on the basis of type and regional market as follows:

On the basis of type this report on global systemic amyloidosis market is segmented as follows, covering major segments type as follows: Primary systemic amyloidosis (PSA), Amyloidosis associated with multiple myelomam, Secondary systemic amyloidosis and others

This report on systemic amyloidosis has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the systemic amyloidosis market. Some of the major companies’ profiles in detail are as follows:
Celgene Corporation
Prothena Corporation Plc
TheraPharm Deutschland GmbH
Johnson & Johnson
Onclave Therapeutics Limited Llc
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 2
1. Systemic Amyloidosis Market – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Systemic Amyloidosis Market– Market Forces
4.1. Drivers
4.1.1. Growing awareness about systemic amyloidosis amongst people
4.1.2. Increasing investment by companies in R&D
4.2. Restraints
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Systemic Amyloidosis Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life cycle Analysis
5.5. Suppliers & Distributors

6. Systemic Amyloidosis Market, By Type
6.1. Primary systemic amyloidosis (PSA)
6.2. Amyloidosis associated with multiple myeloma
6.3. Secondary systemic amyloidosis
6.4. Others

7. Systemic Amyloidosis Market, By Geography
7.1. Europe
7.1.1. Germany
7.1.2. France
7.1.3. Italy
7.1.4. Spain
7.1.5. Russia
7.1.6. U.K.
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.1. China
7.2.2. India
7.2.3. Japan
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America
7.3.1. U.S.
7.3.2. Canada
7.3.3. Mexico
7.4. Rest of the World (RoW)
7.4.1. Brazil
7.4.2. Rest of RoW

8. Systemic Amyloidosis – Market Entropy
8.1. Expansion
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply- Contract

9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
9.1. Celgene Corporation
9.2. Prothena Corporation Plc
9.3. TheraPharm Deutschland GmbH
9.4. Johnson & Johnson
9.5. Amgen Inc.
9.6. Onclave Therapeutics Limited Llc
* More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"Financials would be provided on a best efforts basis for private companies"

10. Appendix
10.1. Abbreviations
10.2. Sources
10.3. Research Methodology
10.4. Bibiliography
10.5. Compilation of Expert Insights
10.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 2